Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Relationship between serum levels of endogenous secretory RAGE and blood pressure in male nondiabetic patients with obstructive sleep apnea

Journal of Human Hypertension volume 29, pages 713–718 (2015)Cite this article

Subjects

Abstract

The interaction of advanced glycation end products (AGE) and their specific cell-surface receptor (RAGE) has an important role in the pathogenesis of cardiovascular disease and diabetic complications. Two isoforms of C-truncated RAGE, soluble RAGE (sRAGE) and endogenous secretory RAGE (esRAGE), may prevent activation of RAGE signaling by acting as decoys. This study investigated whether serum esRAGE and sRAGE levels are associated with blood pressure in nondiabetic patients with obstructive sleep apnea (OSA). Male nondiabetic patients (n=139) with OSA were enrolled. Serum esRAGE and sRAGE levels were examined using enzyme-linked immunosorbent assay. Three consecutive seated systolic blood pressure (SBP) and diastolic blood pressure (DBP) measurements were obtained at 5-min intervals in the morning. In univariate analysis, there was a significant correlation between serum esRAGE and SBP or DBP, but not between serum sRAGE and SBP or DBP. Multiple regression analysis showed that SBP was independently associated with waist circumference, HbA1c, minimum SaO2 and serum esRAGE, and that DBP was independently associated with low-density lipoprotein cholesterol, apnea–hypopnea index, serum AGE and body mass index, but not with serum esRAGE. These results indicated that serum esRAGE levels were inversely associated with blood pressure, especially SBP, in male nondiabetic patients with OSA. esRAGE may have a protective role against hypertension in patients with OSA, and it may be a novel biomarker for OSA patients at high risk of developing cardiovascular diseases.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Durán J, Esnaola S, Rubio R, Iztueta A . Obstructive sleep apnea-hypopnea and related clinical features in a population-based sample of subjects aged 30 to 70 yr. Am J Respir Crit Care Med 2001; 163: 685–689.

    Article  Google Scholar 

  2. Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000; 283: 1829–1836.

    Article  CAS  Google Scholar 

  3. Lenfant C, Chobanian AV, Jones DW, Roccella EJ and Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.

    Article  Google Scholar 

  4. Baguet JP, Barone-Rochette G, Pépin JL . Hypertension and obstructive sleep apnoea syndrome: current perspectives. J Hum Hypertens 2009; 23: 431–443.

    Article  Google Scholar 

  5. Somers VK, Dyken ME, Clary MP, Abboud FM . Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Investig 1995; 96: 1897–1904.

    Article  CAS  Google Scholar 

  6. Elmasry A, Lindberg E, Hedner J, Janson C, Boman G . Obstructive sleep apnoea and urine catecholamines in hypertensive males: a population-based study. Eur Respir J 2002; 19: 511–517.

    Article  CAS  Google Scholar 

  7. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW . Formation of pentosidine during nonenzymatic browning of proteins by glucose. identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 1991; 266: 11654–11660.

    CAS  PubMed  Google Scholar 

  8. Xu Y, Toure F, Qu W, Lin L, Song F, Shen X et al. Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages. J Biol Chem 2010; 285: 23233–23240.

    Article  CAS  Google Scholar 

  9. Tan KC, Chow WS, Lam JC, Lam B, Bucala R, Betteridge J et al. Advanced glycation endproducts in nondiabetic patients with obstructive sleep apnea. Sleep 2006; 29 (3): 329–333.

    Article  Google Scholar 

  10. Lam JC, Tan KC, Lai AY, Lam DC, Ip MS . Increased serum levels of advanced glycation end-products is associated with severity of sleep disordered breathing but not insulin sensitivity in non-diabetic men with obstructive sleep apnoea. Sleep Med 2012; 13: 15–20.

    Article  Google Scholar 

  11. Celec P, Hodosy J, Behuliak M, Pálffy R, Gardlík R, Halčák L et al. Oxidative and carbonyl stress in patients with obstructive sleep apnea treated with continuous positive airway pressure. Sleep Breath 2012; 16: 393–398.

    Article  Google Scholar 

  12. Kotani K, Kimura S, Komada I, Sakane N, Gugliucci A . Continuous positive air pressure treatment reduces serum advanced glycation end products in patients with obstructive sleep apnoea syndrome: a pilot study. Prim Care Respir J 2011; 20 (3): 336–337.

    Article  Google Scholar 

  13. Xu JX, Cai W, Sun JF, Liao WJ, Liu Y, Xiao JR et al. Serum advanced glycation end products are associated with insulin resistance in male nondiabetic patients with obstructive sleep apnea. Sleep Breath (e-pub ahead of print 2 January 2015; doi: 10.1007/s11325-014-1100-z).

  14. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C et al. Advanced glycation end products activate endothelium through signal transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002; 105: 816–822.

    Article  CAS  Google Scholar 

  15. Elmasry A, Lindberg E, Hedner J, Janson C, Boman G . RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 2009; 20: 742–752.

    Article  Google Scholar 

  16. Yan SF, Ramasamy R, Schmidt AM . The RAGE Axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 2010; 106: 842–853.

    Article  CAS  Google Scholar 

  17. Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, Yang H et al. Identification, classification, an expression of RAGE gene splice variants. FASEB J 2008; 22: 1572–1580.

    Article  CAS  Google Scholar 

  18. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002; 106: 2827–2835.

    Article  CAS  Google Scholar 

  19. YanS F, D’Agati V, Schmidt AM, Ramasamy R . Receptor for Advanced Glycation End products (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging. Curr Mol Med 2007; 7: 699–710.

    Article  Google Scholar 

  20. Shoji T, Koyama H, Morioka T, Tanaka S, Kizu A, Motoyama K et al. Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Diabetes 2006; 55: 2245–2255.

    Article  CAS  Google Scholar 

  21. Geroldi D, Falcone C, Emanuele E, D'Angelo A, Calcagnino M, Buzzi MP et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 2005; 23: 1725–1729.

    Article  CAS  Google Scholar 

  22. Momma H, Niu K, Kobayashi Y, Huang C, Chujo M, Otomo A et al. Lower serum endogenous secretory receptor for advanced glycation end product level as a risk factor of metabolic syndrome among Japanese adult men: a 2-year longitudinal study. J Clin Endocrinol Metab 2014; 99: 587–593.

    Article  CAS  Google Scholar 

  23. Narkiewicz K, van de Borne PJ, Cooley RL, Dyken ME, Somers VK . Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation 1998; 98: 772–776.

    Article  CAS  Google Scholar 

  24. Narkiewicz K, Somers VK . Sympathetic nerve activity in obstructive sleep apnoea. Acta Physiol Scand 2003; 177: 385–390.

    Article  CAS  Google Scholar 

  25. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370: 1097–1109.

    Article  CAS  Google Scholar 

  26. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T et al. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis 2009; 204: 288–292.

    Article  CAS  Google Scholar 

  27. Katakami N, Matsuhisa M, Kaneto H, Yamasaki Y . Serum endogenous secretory RAGE levels are inversely associated with carotid IMT in type 2 diabetic patients. Atherosclerosis 2007; 190: 22–23.

    Article  CAS  Google Scholar 

  28. Koyama H, Yamamoto H, Nishizawa Y . Endogenous secretory RAGE as a novel biomarker for metabolic syndrome and cardiovascular diseases. Biomark Insights 2007; 2: 331–339.

    Article  Google Scholar 

  29. Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25: 2587–2593.

    Article  CAS  Google Scholar 

  30. Hudson BI, Dong C, Gardener H, Elkind MS, Wright CB, Goldberg R et al. Serum levels of soluble receptor for advanced glycation end-products and metabolic syndrome: the Northern Manhattan Study. Metabolism 2014; 63: 1125–1130.

    Article  CAS  Google Scholar 

  31. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A et al. A soluble form of the receptor for advanced glycation end products(RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008; 22: 3716–3727.

    Article  CAS  Google Scholar 

  32. Ohe K, Watanabe T, Harada SI, Munesue S, Yamamoto Y, Yonekura H et al. Regulation of alternative splicing of the receptor for advanced glycation endproducts (RAGE) through G-rich cis-elements and heterogenous nuclear ribonucleoprotein H. J. Biochem 2010; 147: 651–659.

    Article  CAS  Google Scholar 

  33. Yamagishi S, Adachi H, Nakamura K, Matsui T, Jinnouchi Y, Takenaka K et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 2006; 55: 1227–1231.

    Article  CAS  Google Scholar 

  34. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T et al. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients. Diabetes Vasc Dis Res 2008; 5: 190–197.

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank all patients who participated in this study. The study was supported by grants from the National Natural Science Funds of China (No. 81160105, 81360017, 81460018) and the Jiangxi Provincial Natural Science Funds of China (No. 2010GZY0325, 20114BAB205006).

Author information

Authors and Affiliations

  1. Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang University, Nanchang, People’s Republic of China

    W Cai, J-F Sun, Y Liu, J-X Xu, J-R Xiao, X-M Duan & J-Y Liu

  2. Department of Medical Biology, Medical College of Nanchang University, Nanchang, People’s Republic of China

    W Cai

  3. Department of Respiratory Medicine, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People’s Republic of China

    W Zhang

Authors
  1. W Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J-F Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J-X Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J-R Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. X-M Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J-Y Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. W Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J-X Xu.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cai, W., Sun, JF., Liu, Y. et al. Relationship between serum levels of endogenous secretory RAGE and blood pressure in male nondiabetic patients with obstructive sleep apnea. J Hum Hypertens 29, 713–718 (2015). https://doi.org/10.1038/jhh.2015.46

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2015.46

Search

Advanced search

Quick links